AUS
NZ
UK
CA
USA
IND
Highlights
- Quest PharmaTech Inc. held its annual general meeting, electing four directors to the board.
- The company reappointed its auditing firm during the meeting.
- Quest PharmaTech granted stock options to directors and officers, pending TSX approval.
Quest PharmaTech Inc. (TSXV:QPT) operates within the biopharmaceutical sector, focusing on innovative cancer treatment solutions. The company is engaged in developing and commercializing products designed to improve the lives of patients through advanced immunotherapy techniques. Quest’s ongoing efforts aim to offer new therapeutic options for combating cancer, leveraging its scientific expertise and research.
Election of Directors
During the recently held annual general meeting, Quest PharmaTech’s shareholders elected four directors to the board. These individuals bring significant experience in various fields, which aligns with the company’s mission of advancing its cancer research initiatives. The board members include J. Mark Lievonen, C.M., FCPA, FCA, LLD, Jeffrey Shon, J.D., Bradley J. Glass, J.D., and Madi R. Madiyalakan, Ph.D. Their collective expertise supports the company's strategic direction, which focuses on developing cutting-edge therapies.
Reappointment of Auditors
Quest PharmaTech also confirmed the reappointment of Kingston Ross Pasnak, LLP, as its auditors. The auditing firm has worked closely with Quest in previous years, and its reappointment reflects the company's commitment to maintaining financial transparency and regulatory compliance. The auditors will continue to provide their expertise in ensuring that all financial reporting remains accurate and meets industry standards.
Stock Options Granted
As part of its corporate governance, Quest PharmaTech announced the granting of stock options to its directors and officers. These options are subject to TSX Venture Exchange approval and are designed to align the interests of the company's leadership with its long-term goals. The stock options were granted at a volume-weighted average exercise price and will expire 10 years from the grant date. This move highlights the company’s efforts to retain talent and leadership to ensure continuity in its research and development projects.
